BioSpace News Archive

Akebia Therapeutics, Inc., a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted one newly-hired employee options to purchase an aggregate of 4,000 shares of Akebia’s common stock on February 29, 2024, as an inducement material to such employee entering into employment with Akebia.

Oragenics, Inc. announced the closing of its previously announced underwritten public offering of 1,400,000 shares of its common stock at a public offering price of $1.50 per share, for gross proceeds of $2.1 million, before deducting underwriting discounts, and offering expenses payable by the Company.

Bristol Myers Squibb announced that its Board of Directors has declared a quarterly dividend of sixty cents per share on the $0.10 par value common stock of the company.

Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, announced the grant of inducement awards to four new employees.

G1 Therapeutics, Inc., a commercial-stage oncology company, announced the grant of inducement stock options exercisable for 2,100 shares of G1’s common stock and 1,050 restricted stock units to one hired employee under the Amended and Restated G1 Therapeutics, Inc. 2021 Inducement Equity Incentive Plan.

The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

Iovance Biotherapeutics, Inc., a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte therapies for patients with cancer, announced that senior leadership plans to present at the following conferences.

LENSAR, Inc. announced that a majority of the independent members of LENSAR’s board of directors granted seven newly-hired non-executive employees stock options to purchase an aggregate of 4,175 shares of the Company’s common stock.

Mezzion Pharmaceuticals is a rare disease company conducting the confirmatory pivotal phase 3 clinical trial in Fontan subjects: The Fontan Udenafil Exercise Longitudinal Assessment Trial- 2, or FUEL-2 trial.

Zentalis® Pharmaceuticals, Inc. announced that on March 1, 2024, the Compensation Committee of Zentalis’ Board of Directors granted non-qualified stock options to purchase an aggregate of 125,000 shares of the Company’s common stock to two newly hired employees.